ipilimumab,nivolumab
bms
['checkmate 914', 'nivo', 'check,mate,914', '/ipi', 'rcc,(-irccs),(-srcc),(-urcc)']
#esmo22 presidential symposium ii highlights: checkmate 914 (lba4) - no dfs benefit with adjuvant nivo/ipi vs placebo for high-risk localized rcc (lba4)
- 33% d/c due to toxicity 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge